Sequence: CRGDKGPDC-GRKKRRQRRRC
| Experiment Id | EXP002456 |
|---|---|
| Paper | Tumor Cell Lysate-Based Multifunctional Nanoparticles Facilitate Enhanced mRNA Delivery and Immune S |
| Peptide | TAT-iRGD |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | 10–12 µg mRNA per dose |
| Mixing Ratio | MLSV/Bim |
| Formulation Format | lipid–polymer nanoparticle |
| Formulation Components | DOTAP + mPEG-PCL + tumor cell lysate + TAT-iRGD |
| Size Nm | 190.00 |
| Zeta Mv | 47.80 |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | B16 melanoma (subcutaneous and lung metastasis), C57 mice |
| Administration Route | intratumoral and intravenous |
| Output Type | tumor suppression / immune activation |
| Output Value | ≈79% tumor growth inhibition (s.c.); ≈63% (lung metastasis) |
| Output Units | |
| Output Notes | Confirmed Bim expression, apoptosis, DC activation |
| Toxicity Notes | No major organ toxicity |
| Curation Notes |